Hepatorenal Syndrome Clinical Trial Review: Drug Development Pipeline Analysis Report

2021-08-17

抗体小分子药物

Los Angeles, USA, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Hepatorenal Syndrome Clinical Trial Review: Drug Development Pipeline Analysis Report Around 3+ key companies are developing therapies for Hepatorenal Syndrome. Noorik Biopharmaceuticals has its Hepatorenal Syndrome drug candidates in the mid to advanced stage (Phase II). An increase in the understanding of diagnosis and treatment of Hepatorenal Syndrome will stimulate the research and developmental activities due to the disease’s effective treatment. DelveInsight’s “Hepatorenal Syndrome Pipeline Insight” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Hepatorenal Syndrome pipeline landscapes. It comprises Hepatorenal Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Hepatorenal Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Hepatorenal Syndrome pipeline products. Some of the key takeaways from the Hepatorenal Syndrome Pipeline Report Get an overview of pipeline landscape @ Hepatorenal Syndrome Clinical Trials Analysis Hepatorenal Syndrome is a type of progressive kidney failure seen in people with severe liver damage, most often caused by cirrhosis. Hepatorenal Syndrome Emerging Drugs Ambrisentan, a small molecule, is a well-characterized endothelin receptor antagonist. Ambrisentan can block the effects of endothelin on both the ETA and ETB receptors. The drug is in phase II of clinical trials for the treatment of Hepatorenal Syndrome. Ambrisentan (N-003) proved safe and well-tolerated with all subjects completing the Phase I study. Ifetroban is a potent antagonist of the thromboxane prostanoid (TPr) receptor, with several functions comprising smooth muscle contraction, platelet aggregation, and inflammation. Preclinical work on this molecule showed that inhibiting TPr with ifetroban enhances cardiac survival while increasing cardiac output in multiple animal models. The drug is in phase II of clinical trials for the treatment of Hepatorenal Syndrome. For further information, refer to the detailed report @ Hepatorenal Syndrome Pipeline Therapeutics Scope of Hepatorenal Syndrome Pipeline Drug Insight · Hepatorenal Syndrome Therapies Late-stage (Phase III) · Hepatorenal Syndrome Therapies Mid-stage (Phase II)· Hepatorenal Syndrome Therapies Early-stage (Phase I) · Hepatorenal Syndrome Preclinical stage and Discovery candidates · Discontinued and Inactive candidates · Thromboxane A2 receptor antagonists· Endothelin A receptor antagonists· Vasopressin receptor agonists · Natural metabolites· Monoclonal antibodies· Small molecule · Subcutaneous · Intravenous· Oral· Intramuscular · Monotherapy· Combination· Mono/Combination Key Questions regarding Current Hepatorenal Syndrome Treatment Landscape and Emerging Therapies Answered in the Pipeline Report Table of Contents Get a customized pipeline report @ Hepatorenal Syndrome Drugs Pipeline Report Other Reports Browse Blog Posts About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

机构